Brent Logan, PhD

Brent R. Logan, PhD

Director & Professor

Locations

Biostatistics

Contact Information

Education

PhD, Northwestern University, Evanston, IL, 2001
MS, Northwestern University, Evanston, IL, 1998
BS, Vanderbilt University, Nashville, TN, 1996

Research Experience

Multiple Comparison Procedures

Research Interests

Dr. Brent Logan joined the Division of Biostatistics in the Summer of 2001. He has methodological research interests in multiple comparison procedures, clinical trial design, and survival analysis. Research in multiple testing includes methods for analyzing multiple endpoints in clinical trials, analysis of dose-response studies, and multiplicity adjustment in functional MRI studies. His interests in clinical trial design include randomized phase 2 clinical trials and biologic assignment trials in bone marrow transplant studies. Recent work in survival analysis has focused on inference for competing risks and multistate models using pseudo-value regression, analysis in the presence of crossing survival curves, and methods for the analysis of complex bone marrow transplant data. He is a biostatistician for the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) and the Center for International Blood and Marrow Transplant Research (CIBMTR), as well as a statistical consultant for the National Marrow Donor Program.

Curriculum Vitae

Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

(Zinter MS, Logan BR, Fretham C, Sapru A, Abraham A, Aljurf MD, Arnold SD, Artz A, Auletta JJ, Chhabra S, Copelan E, Duncan C, Gale RP, Guinan E, Hematti P, Keating AK, Marks DI, Olsson R, Savani BN, Ustun C, Williams KM, Pasquini MC, Dvorak CC.) Biol Blood Marrow Transplant. 2020 Feb;26(2):333-342 PMID: 31563573 PMCID: PMC6943183 SCOPUS ID: 2-s2.0-85074484312 09/30/2019
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.

(Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML.) Blood. 2020 Jan 09;135(2):97-107 PMID: 31738834 SCOPUS ID: 2-s2.0-85077761109 11/19/2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

(Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME.) J Clin Oncol. 2019 Dec 20:JCO1903011 PMID: 31860405 12/21/2019
Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia.

(Knight JM, Rizzo JD, Wang T, He N, Logan BR, Spellman SR, Lee SJ, Verneris MR, Arevalo JMG, Cole SW.) JNCI Cancer Spectr. 2019 Dec;3(4):pkz073 PMID: 31763620 PMCID: PMC6859844 11/26/2019
Quality of Life of Patients with Wiskott Aldrich Syndrome and X-Linked Thrombocytopenia: a Study of the Primary Immune Deficiency Consortium (PIDTC), Immune Deficiency Foundation, and the Wiskott-Aldrich Foundation.

(Shah AJ, Sokolic R, Logan B, Yin Z, Iyengar S, Scalchunes C, Mangurian C, Albert M, Cowan MJ.) J Clin Immunol. 2019 Nov;39(8):786-794 PMID: 31620947 SCOPUS ID: 2-s2.0-85074594346 10/18/2019
Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.

(Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium.) J Clin Immunol. 2019 Oct;39(7):653-667 PMID: 31376032 PMCID: PMC6754755 SCOPUS ID: 2-s2.0-85072546464 08/04/2019
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.

(Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD.) JAMA Oncol. 2019 Dec 12 PMID: 31830234 SCOPUS ID: 2-s2.0-85076620276 12/13/2019
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.

(Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E.) Biol Blood Marrow Transplant. 2019 Nov 19 PMID: 31756536 SCOPUS ID: 2-s2.0-85077165933 11/23/2019
Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.

(Ballen K, Logan BR, Chitphakdithai P, Kuxhausen M, Spellman SR, Adams A, Drexler RJ, Duffy M, Kemp A, King R, Babic A, Delaney C, Karanes C, Kurtzberg J, Petz L, Scaradavou A, Shpall EJ, Smith C, Confer DL, Miller JP.) Biol Blood Marrow Transplant. 2019 Nov 19 PMID: 31756539 SCOPUS ID: 2-s2.0-85077166820 11/23/2019
Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults.

(Majhail NS, Mau LW, Chitphakdithai P, Denzen EM, Joffe S, Lee SJ, LeMaistre CF, Loberiza F, Parsons SK, Repaczki-Jones R, Robinett P, Douglas Rizzo J, Murphy E, Logan B, Le-Rademacher J.) Bone Marrow Transplant. 2019 Nov 18 PMID: 31740767 SCOPUS ID: 2-s2.0-85075369259 11/20/2019
Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.

(Martens MJ, Logan BR.) Lifetime Data Anal. 2019 Nov 15 PMID: 31729633 11/16/2019
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.

(Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B.) JAMA Oncol. 2019 Sep 26 PMID: 31556923 PMCID: PMC6763979 SCOPUS ID: 2-s2.0-85072756041 09/27/2019